

Board of Directors
Declaration of Interests 2026/27

Non-Executive Directors	Position	Declaration of Interest
Sir Douglas Flint	Chair	- Chairman, The Royal Marsden Cancer Chairty, December 2022 to date - Prudential plc - Chair - 3-4 days per week as of March 2026 - Aberdeen Group plc - Chair - stepping down 28 April 2026 - IP Group plc - Chair - stepping down 18th June 2026
William Jackson	Senior Independent Director	- Director, LTA Chair from July 2025 - Independent Director, IFM Investors Pty
Elizabeth Adekunle	Non-Executive Director	- Chaplain to His Majesty the King - present - Non-Executive Director, Berkeley Group Holdings pls - Governor and Advisory role Wellington College - Advisory role Met Police Ethics Committee
Ted Baker	Non-Executive Director	- Chair of Health Services Safety Investigation Body since October 2023 - Trustee of Royal College of Paediatrics and Child Health since December 2025 - Member of GS1 UK Healthcare Advisory Board, since 2023. - Chair of Independent Advisory Group for Healthcare Quality Improvement Partnership (HQIP) Medical and Surgical Outcomes Review Programme since 2025
Jane Bentall	Non-Executive Director	- Senior Independent Director, and Chair of Audit Committee, Safestore plc, 25 days per annum, current - Own consultancy, JB Leisure Consulting Ltd, 0.5 days per week on average, current
Katie Bickerstaffe	Non-Executive Director	- Barratt Redrow plc, Non-Executive Director, role held since March 2021. 25 days per year time commitment. - J Sainsbury plc. Non-Executive Director, role held since July 2025. 25 days per year time commitment - England and Wales Cricket Board, Senior Independent Director, role held since September 2019. 20 days per year. - Diploma plc. Senior Independent Director. Role held since October 2024. Time commitment 25 days per year.

		• Aberdeen plc Non-Executive Director. Role held since October 2024. Time commitment 25 days per year • Consultancy Director for Flocon de Neige • Diploma plc 2120 shares • Barratt Redrow plc 34,930 shares
Alison Dickinson	Non-Executive Director	• Hospital Director, Nuffield Health Leicester Hospital, December 2024 – current • Shareholder Spire Healthcare
Baroness Rona Fairhead	Non-Executive Director	• RS Group plc (Chairman) - 7 Board meetings per annum • Oracle Corporation (NED) - 9 Board (4) / (5) Audit Committee Meetings • CVC Capital Partners (SID) - 5 Board / Committee Meetings • Hong Kong Exchanges and Clearing (Advisory Council Member) - 2 days • Shareholder (as NED) in Oracle Corporation (incl. Oracle Health) • B2B NEW YORK LIMITED - Director & Shareholder • FAIRHEAD TRUSTEES LIMITED - Director & Shareholder
Professor Kristian Helin	Non-Executive Director	• Chief Executive, President and Professor at The Institute of Cancer Research. • Co-founder, consultant of Dania Therapeutics: 3 hours per week. • Non-executive roles in Scientific Advisory Boards on non--for-profit organisations • Scientific Advisory Board (Chair) Department of Experimental Oncology, European Institute of Oncology, Milan, Italy: 1-2 days per year. • Scientific Advisor, the Institute of Medical Science, University of Tokyo, Japan: very little activity, less than an hour per year. • SAB, CRUK Manchester Institute: 1-2 days every other year. • SAB, Human Technopole, Milan, Italy: 6 x 2 hours per year and 1 day per year. • SAB, ISREC, EPFL, Lausanne, Switzerland: 1 day every other year • SAB (Chair) Italian Institute of Genomic Medicine: 1 day every other year • SAB Cancer Research UK Scotland Centre: 2 days every other year • Danish Cancer Society's Strategic Research Council: 1.5 day per year • Editorial Advisory Boards: EMBO Reports (2004-), EMBO J (2004-), Developmental Cell (2012-) and EMBO Press Advisory Board (2017-)

Executive Directors	Position	Declaration of Interest
Dame Cally Palmer	Chief Executive	- Trustee of The Royal Marsden Cancer Charity, September 2010 – to date as CE of The Royal Marsden - Trustee of the Institute of Cancer Research, June 1998 - to date as CE of The Royal Marsden - Main Board Director, King Faisal Specialist Hospital and Research Centre, Approx 8 meetings per year.
Sofia Colas	Chief Operating Officer	- Director and Chairperson of RM Medicines Limited, wholly owned subsidiary of The Royal Marsden - Epic dinner hosted at Bristol conference
Mairead Griffin	Chief Nurse	Nil
Adedoyin Ogunbiyi	Chief Finance Officer	Nil
Dr Emma Kipps	Interim Chief Medical Officer	- Private clinical practice is exclusively at Royal Marsden Hospital within agreed job plan - Pfizer speaker fees, honoraria Novartis consultancy, honoraria Roche consultancy, astra Zeneca speaker fees